1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Hyperoxaluria: new trials by email Literature Review of Hyperoxaluria trials Research Report on Hyperoxaluria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long Term Extension Study in Patients With Primary Hyperoxaluria DCR-PHXC - Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2) | Phase 3 | Active not recruiting | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 75 | 2019-07-09 | 2026-10-08 |
Genetic Diseases, Inborn (1) · Hyperoxaluria, Primary (1) · Kidney Diseases (1) · Primary hyperoxaluria type 1 (1) · Primary hyperoxaluria type 2 (1) · Urologic Diseases (1)
Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Nutritional and Metabolic Diseases (1) · Urogenital Diseases (1)
nedosiran (1)
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1)
Australia (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Lebanon (1) · Netherlands (1) · Norway (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)